TrialCompass TCL
Back to results
NARecruitingPriority 4 · Lower priorityNCT05662540

PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This NA trial is evaluating Positron Emission Tomography/Magnetic Resonance (PET/MR) as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 14 Years to 70 Years years
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Positron Emission Tomography/Magnetic Resonance (PET/MR) (DEVICE): 18F-FDG PET/MR imaging (manufacturer: Siemens, model: Biography mMR). Research devices are marketed products.

Drugs / treatments
Positron Emission Tomography/Magnetic Resonance (PET/MR)
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma

NCT05662540

Phase: NA | Status: Recruiting | Priority: Lower

Plain-language summary

This NA trial is evaluating Positron Emission Tomography/Magnetic Resonance (PET/MR) as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join

  • Age 14 Years to 70 Years years
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

What's being tested

Positron Emission Tomography/Magnetic Resonance (PET/MR) (DEVICE): 18F-FDG PET/MR imaging (manufacturer: Siemens, model: Biography mMR). Research devices are marketed products.

Drugs / treatments: Positron Emission Tomography/Magnetic Resonance (PET/MR)

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 40 patients

Primary endpoint: The sensitivity, specificity and accuracy of PET/MR in the staging of newly diagnosed NK/T-cell lymphoma patients; The sensitivity, specificity and accuracy of PET/MR in the efficacy evaluation of newly diagnosed NK/T-cell lymphoma patients

Ages: 14 Years to 70 Years

Start date: 2023-05-26 | Est. completion: 2026-10

Locations

0 US sites · 1 total

Contact

Weili Zhao | zwl_trial@163.com | +862164370045

Sponsor: Ruijin Hospital (OTHER)

Tags

ENKTL · Newly diagnosed

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT05662540

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.